← Banking With Billy News

Cullinan Therapeutics said positive FDA feedback after its End-of-Phase 1 meeting will advance CLN-049 into Phase 2. The FLT3xCD3 T-cell engager is headed for a

BWB News TV • 2026-07-28 11:12 UTC • By Billy Odell Tucker-Robinson
Cullinan Therapeutics said positive FDA feedback after its End-of-Phase 1 meeting will advance CLN-049 into Phase 2. The FLT3xCD3 T-cell engager is headed for a
Cullinan Therapeutics said positive FDA feedback after its End-of-Phase 1 meeting will advance CLN-049 into Phase 2. The FLT3xCD3 T-cell engager is headed for a potentially registrational trial in relapsed or refractory AML.
Share this article
𝕏 X / Twitter Facebook LinkedIn WhatsApp
📚 More from Billy’s World
📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly